Corvus Pharmaceuticals Inc CRVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRVS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.53
- Day Range
- $1.41–1.54
- 52-Week Range
- $0.98–4.19
- Bid/Ask
- $1.40 / $1.72
- Market Cap
- $72.09 Mil
- Volume/Avg
- 69,358 / 220,842
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's main product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.corvuspharma.com
Comparables
Valuation
|
Metric
|
CRVS
|
CLDX
|
ALLK
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.07 | 5.10 | 0.62 |
Price/Sales | — | 275.86 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CRVS
CLDX
ALLK
Financial Strength
|
Metric
|
CRVS
|
CLDX
|
ALLK
|
|---|---|---|---|
Quick Ratio | 3.96 | 13.69 | 8.27 |
Current Ratio | 4.07 | 13.87 | 9.31 |
Interest Coverage | — | — | — |
Quick Ratio
CRVS
CLDX
ALLK
Profitability
|
Metric
|
CRVS
|
CLDX
|
ALLK
|
|---|---|---|---|
Return on Assets (Normalized) | −44.12% | −30.49% | −45.63% |
Return on Equity (Normalized) | −52.40% | −33.19% | −58.46% |
Return on Invested Capital (Normalized) | −53.49% | −32.85% | −53.25% |
Return on Assets
CRVS
CLDX
ALLK
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zjzwcgzsh | Bzhp | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pfbbwdkkx | Blkdc | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yqdhlrfy | Yktxgg | $98.6 Bil | |
MRNA
| Moderna Inc | Sglvrvs | Zxdqr | $41.0 Bil | |
ARGX
| argenx SE ADR | Xpmcbzrg | Zjh | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Gmgprxdc | Hxrln | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jfwhvgsy | Dkdvn | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vmprkyrc | Dywgv | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qwnglbcwrm | Rpqxyz | $12.6 Bil | |
INCY
| Incyte Corp | Lhhrzrzg | Vqvthby | $12.0 Bil |